
British competition regulator CMA said Friday that it has referred NortonLifeLock Inc.’s proposed acquisition of Avast for further investigation over competition concerns.
The Competition and Markets Authority said that the parties had until Wednesday to offer undertakings that it may accept to mitigate competition concerns. The companies said on March 18 that they wouldn’t provide any such remedies.
As a result, the regulator has decided to refer the merger for an in-depth phase 2 investigation.
The CMA had previously warned that the merger could lead to reduced competition in the U.K. market, as both companies sell cyber-safety software and are close competitors with few other significant rivals.
US software company NortonLifeLock previously said it found the CMA’s decision surprising and that it was confident the merger should be approved. It further said it expects the deal with Czech software developer Avast to become effective in mid-to-late 2022.
The deal, announced in August for up to US$8.6 billion in cash and shares, would further NortonLifeLock’s efforts to consolidate itself as a leader in consumer security software, a growing area for increasingly digital economies.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas